MLICM
ALXN

Metropolitan Life Insurance Company (MetLife)’s Alexion Pharmaceuticals ALXN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-26,525
Closed -$4.87M – 2871
2021
Q2 		$4.87M Sell
26,525
-1,805
-6% -$310K 0.07% 226
2021
Q1 		$4.33M Sell
28,330
-1,359
-5% -$210K 0.06% 244
2020
Q4 		$4.64M Sell
29,689
-1,589
-5% -$204K 0.07% 216
2020
Q3 		$3.58M Sell
31,278
-1,576
-5% -$170K 0.06% 252
2020
Q2 		$3.69M Sell
32,854
-7,455
-18% -$791K 0.07% 235
2020
Q1 		$3.62M Sell
40,309
-484
-1% -$47.5K 0.07% 220
2019
Q4 		$4.41M Sell
40,793
-429
-1% -$45.9K 0.07% 236
2019
Q3 		$4.04M Sell
41,222
-562
-1% -$63.3K 0.07% 244
2019
Q2 		$5.47M Buy
41,784
+2,421
+6% +$312K 0.09% 195
2019
Q1 		$5.32M Sell
39,363
-1,524
-4% -$190K 0.1% 181
2018
Q4 		$3.98M Sell
40,887
-461
-1% -$54.5K 0.08% 207
2018
Q3 		$5.75M Sell
41,348
-986
-2% -$124K 0.1% 178
2018
Q2 		$5.26M Buy
42,334
+354
+0.8% +$41.4K 0.09% 201
2018
Q1 		$4.68M Sell
41,980
-197
-0.5% -$23.5K 0.07% 221
2017
Q4 		$5.04M Sell
42,177
-70,934
-63% -$8.64M 0.07% 216
2017
Q3 		$15.9M Sell
113,111
-2,156
-2% -$293K 0.1% 180
2017
Q2 		$14M Sell
115,267
-3,858
-3% -$449K 0.1% 194
2017
Q1 		$14.4M Sell
119,125
-1,474
-1% -$190K 0.1% 193
2016
Q4 		$14.8M Sell
120,599
-3,367
-3% -$412K 0.11% 179
2016
Q3 		$15.2M Sell
123,966
-1,414
-1% -$182K 0.11% 172
2016
Q2 		$14.6M Sell
125,380
-1,685
-1% -$239K 0.11% 176
2016
Q1 		$17.7M Sell
127,065
-1,739
-1% -$255K 0.14% 140
2015
Q4 		$24.6M Sell
128,804
-2,027
-2% -$354K 0.19% 101
2015
Q3 		$20.5M Sell
130,831
-1,087
-0.8% -$198K 0.15% 135
2015
Q2 		$23.8M Buy
131,918
+13,434
+11% +$2.32M 0.17% 125
2015
Q1 		$20.5M Buy
118,484
+540
+0.5% +$97.7K 0.15% 139
2014
Q4 		$21.8M Sell
117,944
-167
-0.1% -$30.9K 0.15% 134
2014
Q3 		$19.6M Sell
118,111
-1,899
-2% -$312K 0.14% 142
2014
Q2 		$18.8M Sell
120,010
-5,388
-4% -$851K 0.13% 158
2014
Q1 		$19.1M Sell
125,398
-928
-0.7% -$148K 0.13% 155
2013
Q4 		$16.8M Sell
126,326
-2,140
-2% -$257K 0.12% 170
2013
Q3 		$14.9M Sell
128,466
-788
-0.6% -$86.5K 0.11% 179
2013
Q2 		$11.9M Buy
+129,254
New +$12.5M 0.1% 217

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ALXN Position: Q3 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 26,525 shares — an estimated $4.87M sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $24.6M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 26,525 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.87M.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Alexion Pharmaceuticals position peaked at $24.6M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2021, filed 15 Nov 2021.